| Trial ID: | L0195 |
| Source ID: | NCT00796679
|
| Associated Drug: |
Paricalcitol
|
| Title: |
Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: paricalcitol
|
| Outcome Measures: |
Primary: Change in left ventricular mass index determined by MRI, 1 year | Secondary: Change in left atrial and ventricular volumes, systolic and diastolic function, carotid intima-media thickness, flow mediated dilation, pulse wave velocity, serum inflammatory and cardiac biomarkers, intact PTH, 24-hour urine protein and renal function, 1 year
|
| Sponsor/Collaborators: |
Sponsor: The University of Hong Kong | Collaborators: Abbott
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-10
|
| Completion Date: |
2011-06
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-10
|
| Locations: |
Queen Mary Hospital, Hong Kong, 0000, Hong Kong|University of Hong Kong, Queen Mary Hospital, Hong Kong, 0000, Hong Kong
|
| URL: |
https://clinicaltrials.gov/show/NCT00796679
|
